Log In
Print
BCIQ
Print
Print this Print this
 

CPX-351

  Manage Alerts
Collapse Summary General Information
Company Celator Pharmaceuticals Inc.
DescriptionLiposomal formulation of cytarabine and daunorubicin encapsulated at a 5:1 molar ratio using CombiPlex technology
Molecular Target DNA polymerase ; Topoisomerase II (TOP2)
Mechanism of ActionTopoisomerase II inhibitor; DNA polymerase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationAcute myelogenous leukemia (AML)
Indication DetailsFirst-line treatment of high-risk acute myelogenous leukemia (AML); Treat acute myelogenous leukemia (AML); Treat children with acute myeloid leukemia (AML); Treat first relapse of acute myeloid leukemia (AML); Treat high-risk untreated myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML); Treat newly diagnosed acute myelogenous leukemia (AML); Treat relapsed or refractory high-risk myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML)
Regulatory Designation

U.S. - Orphan Drug (Treat acute myelogenous leukemia (AML));
EU - Orphan Drug (Treat acute myelogenous leukemia (AML))

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today